|本期目录/Table of Contents|

[1]桂 真,蒲红兵,张 蓓,等.嗜酸性粒细胞水平与支气管扩张吸入性糖皮质激素疗效的相关性[J].中华肺部疾病杂志,2024,(06):1020-1023.[doi:10.3877/cma.j.issn.1674-6902.2024.06.033
]
点击复制

嗜酸性粒细胞水平与支气管扩张吸入性糖皮质激素疗效的相关性(PDF)

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:
期数:
2024年06期
页码:
1020-1023
栏目:
短篇论著
出版日期:
2024-12-25

文章信息/Info

Title:
-
作者:
桂 真; 蒲红兵; 张 蓓; 王 钰; 蔡嘉敏; 彭诗卉
518109 深圳,深圳市龙华区人民医院全科医学科
Author(s):
-
关键词:
嗜酸性粒细胞;  支气管扩张症;  糖皮质激素;  相关性;  动脉血二氧化碳分压
Keywords:
-
分类号:
R562.2
DOI:
10.3877/cma.j.issn.1674-6902.2024.06.033
摘要:
-
Abstract:
-

参考文献/References:

1 Mertsch P, Ringshausen FC, Rademacher J. [Bronchiectasis][J]. MMW Fortschr Med, 2023,165(18): 54-57.
2 Guan WJ, Xu JF, Luo H, et al. A double-blind randomized placebo-controlled phase 3 trial of tobramycin inhalation solution in adults with bronchiectasis with pseudomonas aeruginosa infection[J]. Chest, 2023,163(1): 64-76.
3 Perea L, Cantó E, Suarez-cuartin G, et al. A cluster analysis of bronchiectasis patients based on the airway immune profile[J]. Chest, 2021, 159(5): 1758-1767.
4 Aliberti S, Goeminne PC, O'donnell AE, et al. Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: international consensus recommendations[J]. Lancet Respir Med, 2022, 10(3): 298-306.
5 安旭灿. 小剂量红霉素联合沙美特罗替卡松气雾剂治疗支气管扩张症的效果[J]. 河南医学研究, 2021, 30(2): 291-293.
6 支气管扩张症专家共识撰写协作组, 中华医学会呼吸病学分会感染学组. 中国成人支气管扩张症诊断与治疗专家共识[J]. 中华结核和呼吸杂志, 2021, 44(4): 311-321.
7 Tsikrika S, Dimakou K, Papaioannou AI, et al. The role of non-invasive modalities for assessing inflammation in patients with non-cystic fibrosis bronchiectasis[J]. Cytokine, 2017, 99(1): 281-286.
8 王 玲, 师一涵, 杨 恒, 等. 支气管扩张症年度进展2021[J]. 中华结核和呼吸杂志, 2022, 45(6): 592-597.
9 Aliberti S, Sotgiu G, Blasi F, et al. Blood eosinophils predict inhaled fluticasone response in bronchiectasis[J]. Eur Respir J, 2020, 56(2): 2000453.
10 Martinez-garcia MA, Posadas T, Sotgiu G, et al. Role of inhaled corticosteroids in reducing exacerbations in bronchiectasis patients with blood eosinophilia pooled post-hoc analysis of 2 randomized clinical trials[J]. Respir Med, 2020, 172(1): 106127.
11 唐楚娟, 刘 聪, 成 玮, 等. 慢性阻塞性肺疾病急性加重相关因素及外周血嗜酸性粒细胞指导吸入性糖皮质激素使用的价值[J]. 中国医师杂志, 2023, 25(7): 970-976.
12 李燕敏, 高 伟, 武维屏, 等. 调肝理肺饮提高吸入中高剂量糖皮质激素哮喘患者症状控制水平的临床研究[J]. 国际中医中药杂志, 2023, 45(8): 953-958.
13 WU C. Research progress of serum eosinophil in chronic obstructive pulmonary disease and asthma[J]. Open Life Sci, 2023, 18(1): 20220779.
14 Gai X, Guo C, Zhang L, et al. Serum glycerophospholipid profile in acute exacerbation of chronic obstructive pulmonary disease[J]. Front Physiol, 2021, 12(1): 646010.
15 Keir HR, Shoemark A, Dicker AJ, et al. Neutrophil extracellular traps, disease severity, and antibiotic response in bronchiectasis: an international, observational, multicohort study[J]. Lancet Respir Med, 2021, 9(8): 873-884.
16 Song Y, Wang D, Ma J, et al. The value of sST2 combined with EOS count in the diagnosis and prognosis evaluation of bronchiectasis complicated with asthma[J]. Minerva Surg, 2023, 78(6): 744-746.
17 Martínez-garcía MA, Olveira C, Girón R, et al. Reliability of blood eosinophil count in steady-state bronchiectasis[J]. Pulmonology, 2024: S2531-0437(23)00204-0.
18 黄晓娜. 支气管扩张症急性加重患者预后不良的危险因素分析[D]. 兰州大学, 2023: 31-45.
19 Shoemark A, Shteinberg M, De Soyza A, et al. Characterization of eosinophilic bronchiectasis: a european multicohort study[J]. Am J Respir Crit Care Med, 2022, 205(8): 894-902.
20 Del Pozo V, Bobolea I, Rial MJ, et al. Expert consensus on the use of systemic glucocorticoids for managing eosinophil-related diseases[J]. Front Immunol, 2023, 14(1): 1310211.
21 Yi F, Zhan C, Liu B, et al. Effects of treatment with montelukast alone, budesonide/formoterol alone and a combination of both in cough variant asthma[J]. Respir Res, 2022, 23(1): 279.
22 Aliska G, Putra AE, Anggrainy F, et al. The exploration of glucocorticoid pathway based on disease severity in COVID-19 patients[J]. Heliyon, 2024, 10(1): e23579.
23 Allam Vsrr, Pavlidis S, Liu G, et al. Macrophage migration inhibitory factor promotes glucocorticoid resistance of neutrophilic inflammation in a murine model of severe asthma[J]. Thorax, 2023, 78(7): 661-673.
24 Ashdown HF, Smith M, Mcfadden E, et al. Blood eosinophils to guide inhaled maintenance therapy in a primary care COPD population[J]. ERJ Open Res, 2022, 8(1): 00606-02021.
25 Kwok Wc, Tam Tcc, Lam Dcl, et al. Blood eosinophil percentage as a predictor of response to inhaled corticosteroid in bronchiectasis[J]. Clin Respir J, 2023, 17(6): 548-555.
26 唐友文. 不同血嗜酸性粒细胞水平下的非CF支气管扩张急性加重期患者临床特征分析[D]. 南昌大学医学部, 2023.
27 卢亚茹. 血嗜酸性粒细胞与慢性阻塞性肺疾病对糖皮质激素治疗反应的关系[J]. 慢性病学杂志, 2022, 23(9): 1418-1420.
28 Wang X, Villa C, Dobarganes Y, et al. Phenotypic clustering in non-cystic fibrosis bronchiectasis patients: the role of eosinophils in disease severity[J]. Int J Environ Res Public Health, 2021, 18(16): 8431.
29 Dalin Da, Løkke A, Kristiansen P, et al. A systematic review of blood eosinophils and continued treatment with inhaled corticosteroids in patients with COPD[J]. Respir Med, 2022, 198(1): 106880.
30 Martínez-garcía MÁ, Méndez R, Olveira C, et al. The u-shaped relationship between eosinophil count and bronchiectasis severity: the effect of inhaled corticosteroids[J]. Chest, 2023, 164(3): 606-613.

备注/Memo

备注/Memo:
通信作者: 桂 真, Email: guizhen55@163.com
更新日期/Last Update: 2024-12-25